Tracers / [188Re]Re-RC-160

[188Re]Re-RC-160

Also written as Re-188-RC-160

Radionuclide: Re-188 t½ 1020 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 0

Lung cancer Preclinical only, no clinical indication yet

What it is

Compound class: Somatostatin analog (octreotide-based peptide)
Target / mechanism: Somatostatin receptor targeting via octreotide PMID 8878464
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [188Re]Re-RC-160, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 8878464: 'octreotide was directly labeled with 188Re by reducing disulfide bonds'. Stage 26: this agent has NO own synthesis/characterisation data in the current corpus -- its only linked run(s) were unlinked (empty-quote recheck: appeared only as a control/comparator or in the wrong article).